Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals Inc.

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Tarsus Pharmaceuticals, with a price target of $95.0...

Tarsus Pharmaceuticals (TARS) Receives a Buy from LifeSci Capital

Barclays analyst Jenna Davidner maintained a Buy rating on Tarsus Pharmaceuticals today and set a price target of $100.00. Davidner covers the Heal...

Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tarsus Pharmaceuticals (TARS) and IDEAYA Biosciences...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARS	$61.45	+0.79%	723.24K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TARS	$61.45	+0.8%	723.24K
3
4
5
6

TARS

TARS

Get Tarsus Pharmaceuticals Inc. Data in Excel

Get Tarsus Pharmaceuticals Inc. Data in Excel